Doctors and scientists have been fighting for decades to solve the problem of cure for hepatitis C. New drugs are being developed and improved treatment regimens are being developed. Until recently, the most common method of treatment, depending on the genotype of hepatitis C virus, was the use of a combination of interferon and ribavirin. Recovery occurred in 70-80% of patients with genotype 2, 3 and 45-70% with genotype 1, 4.
Currently, all patients with hepatitis C virus are recommended to use direct antiviral drugs (DAA). These drugs have an impact on the replication of non-structural proteins of the virus NS3, NS5A, NS5B. The first generation of DAAS differed in their effects on certain virus genotypes, resistance barriers, and side effects. To date, the world has registered and second-generation drugs, characterized by improved performance and less side effects. For preparations of the second generation characterized pangenotypic, that is, they act on a broad range of genotypes of the virus. In the who recommendation of July 2018, as the most effective drugs for treatment, there are combined drugs that have a pangenotypic effect.
The presence of a history of comorbidities, a combination of hepatitis C and B, hepatitis C and HIV is characterized by a more severe course of the disease and makes an unfavorable prognosis. Also, the choice of treatment and prognosis for it is influenced by factors such as the presence of severe fibrosis or cirrhosis of the liver.